Testing two drugs together for triple negative breast cancer that spread to the brain
Original title: A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study in people, and the answers are not in yet.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a pair of drugs in people whose breast cancer has reached the brain.
Who this trial is for. This trial is for people with advanced triple negative breast cancer. Their cancer has spread to the brain. It tests two drugs given together, utidelone and capecitabine.
Where it stands. The study is measuring how well the two drugs work and how safe they are. Everyone in the study gets the same two drugs. The trial has not reported results. So no one knows yet if this helps.
What this means, and what it doesn't
What it could mean: People with this kind of cancer have few choices for treatment. This study is looking for one that may help. Someone who fits the study could ask their care team about it.
What it doesn't mean: A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help. It is not a promise of a cure. These drugs may not work, and they can cause side effects.
Source: ClinicalTrials.gov, October 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.